Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 6, 2007

Aradigm and CyDex Combine Expertise to Tackle Asthma and COPD

  • Aradigm and CyDex are collaborating to combine products for the treatment of asthma and chronic obstructive pulmonary diseases (COPD).

    “Putting together Cydex’ aqueous formulation capabilities with Aradigm’s palm-size AERx Essence inhalation delivery system has the potential to generate a family of attractive novel therapies for asthma and COPD patients,” John Siebert, CEO of CyDex said.

    Under the two-year agreement, Aradigm will bear 60% of the costs of development, and CyDex will be responsible for the rest. Third-party licensing and sales revenues will be shared in the same ratio.

    The companies will develop and commercialize products containing inhaled corticosteroids, anticholinergics, and beta-2 agonists.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »